Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.72 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meglitinide SCHEMBL37926 | 1.00 | DNMT3A (0.78) | DNMT3AHDAC1HDAC6NLRP3GAA | |
| SCHEMBL11354611 | 0.91 | DNMT3A (0.75) | DNMT3AHDAC1HDAC6NLRP3GAA | |
| SCHEMBL11360335 | 0.91 | DNMT3A (0.78) | DNMT3AHDAC1HDAC6NLRP3GAA | |
| SCHEMBL11479096 | 0.90 | HDAC1 (0.71) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL1153776 | 0.90 | DNMT3A (0.67) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL3784241 | 0.89 | DNMT3A (0.80) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL8261934 | 0.89 | DNMT3A (0.84) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL1154792 | 0.88 | DNMT3A (0.62) | DNMT3AHDAC1HDAC6NLRP3GAA | |
| SCHEMBL30381560 | 0.88 | HDAC1 (0.79) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL11481071 | 0.88 | HDAC1 (0.79) | DNMT3AHDAC1HDAC6NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | claimed |
| EP-3758692-B1 | COMPOSITIONS AND METHODS FOR TREATING PAIN | UNIV MARYLAND (US) | 2024-08-21 | — | — | EP | claimed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | claimed |
| EP-3328388-B1 | A PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN | LILLY CO ELI (US) | 2023-12-27 | — | — | EP | claimed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116437914-A | Glucokinase activators for the treatment of diabetes with liver injury | 华领医药技术（上海）有限公司 | 2023-07-14 | — | — | CN | claimed |
| EP-3628101-B1 | METHOD AND SYSTEM FOR MANAGING LIFESTYLE AND HEALTH INTERVENTIONS | BETTER THERAPEUTICS LLC (US) | 2023-06-07 | — | — | EP | claimed |
| EP-3432877-B1 | D-ALPHA-METHYLDOPA FOR TREATING AUTOIMMUNE DISEASE | IMMUNOMOLECULAR THERAPEUTICS INC (US) | 2023-01-11 | — | — | EP | claimed |
| EP-3359162-B1 | METHODS OF TREATING INJURIES OR CONDITIONS RELATED TO CNS EDEMA | BIOGEN CHESAPEAKE LLC (US) | 2022-12-21 | — | — | EP | claimed |
| EP-3302458-B1 | METHODS OF PREVENTING AND TREATING AUTOIMMUNITY | UNIV COLORADO REGENTS (US) | 2022-09-07 | — | — | EP | claimed |
| EP-3801542-B1 | METHODS OF TREATING SUBJECTS HAVING DIABETES WITH CHRONIC KIDNEY DISEASE | POXEL SA (FR) | 2022-08-10 | — | — | EP | claimed |
| CN-120018857-A | Combination therapy of GPRC5D TCB and IMID | 豪夫迈·罗氏有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119470873-A | Biomarkers for metabolic syndrome | 佐拉生物科学公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118955413-A | Emamiger hydrochloride preparation method of LIMING | 宁夏恒康科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118159654-A | Inhibin subunit beta E (INHBE) modulator compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-3826627-B1 | ORALLY ADMINISTERABLE PHARMACEUTICAL DOSAGE FORM WITH MODIFIED RELEASE | BAYER AG (DE) | 2023-10-18 | — | — | EP | disclosed |
| CN-116769054-A | Bispecific signaling agents and uses thereof | 奥里尼斯生物科学私人有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116437914-A | Glucokinase activators for the treatment of diabetes with liver injury | 华领医药技术（上海）有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-109071663-B | Bispecific signaling agents and uses thereof | 奥里尼斯生物科学私人有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-111171047-B | Fused dihydro-4H-pyrazolo [5,1-C ] [1,4] oxazinyl compounds for the treatment of CNS disorders | 赛诺维信制药公司 | 2023-06-23 | — | — | CN | disclosed |